Relationship of Immunosuppression to Epstein-Barr Viral Load and Lymphoproliferative Disease in Pediatric Heart Transplant Patients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 1, 2008, Pages 100-105

  Schubert, Stephan ^a   Renner, Christiane ^a   Hammer, Markus ^b   Abdul Khaliq, Hashim ^a   Lehmkuhl, Hans Brendan ^a   Berger, Felix ^a   Hetzer, Roland ^a   Reinke, Petra ^b  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EDETIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHOPROLIFERATIVE DISEASE; MALE; PEDIATRICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS LOAD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 37749022131     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.09.027     Document Type: Article

References (32)

1. Trofe J., Buell J.F., Beebe T.M., et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 5 (2005) 775-780
2. Halkos M.E., Miller J.I., Mann K.P., Miller D.L., and Gal A. Thoracic presentations of posttransplant lymphoproliferative disorders. Chest 126 (2004) 2013-2020
3. Ross M., Kouretas P., Gamberg P., et al. Ten- and 20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 261-270
4. Cao S., Cox K., Esquivel C.O., et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation 66 (1998) 851-856
5. Dharnidharka V.R., Sullivan E.K., Stablein D.M., Tejani A.H., and Harmon W.E. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71 (2001) 1065-1068
6. Cohen A.H., Sweet S.C., Mendeloff E., et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 161 (2000) 1252-1255
7. Raj R., and Frost A.E. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 24 (2005) 671-679
8. Nalesnik M.A. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 8 (1996) 139-148
9. Dror Y., Greenberg M., Taylor G., et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 67 (1999) 990-998
10. Nalesnik M.A. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 159 (2002) 9-18
11. Nalesnik M.A. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transplant Infect Dis 3 (2001) 88-96
12. Leblond V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 16 (1998) 2052-2059
13. Lamy M.E., Favart A.M., Cornu C., et al. Epstein-Barr virus infection in 59 orthotopic liver transplant patients. Med Microbiol Immunol (Berl) 179 (1990) 137-144
14. Nalesnik M.A. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 2 (1997) 33-40
15. Zangwill S.D., Hsu D.T., Kichuk M.R., et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 17 (1998) 1161-1166
16. Aalto S.M., Linnavuori K., Peltola H., et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 56 (1998) 186-191
17. Merlino C., Cavallo R., Bergallo M., et al. Quantitative PCR in EBV-infected renal transplant patients. New Microbiol 24 (2001) 223-229
18. Stevens S.J., Verschuuren E.A., Pronk I., et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97 (2001) 1165-1171
19. Orentas R.J., Schauer Jr. D.W., Ellis F.W., et al. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 7 (2003) 305-314
20. Kogan-Liberman D., Burroughs M., Emre S., Moscona A., and Schneider B.L. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr 33 (2001) 445-449
21. Malouf M.A., Chhajed P.N., Hopkins P., et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 21 (2002) 547-554
22. Lucas K.G., Burton R.L., Zimmerman S.E., et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91 (1998) 3654-3661
23. Krieger N., Martinez O.M., Krams S.M., et al. Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transplant 6 (2000) 62-66
24. Micallef I.N., Chhanabhai M., Gascoyne R.D., et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 22 (1998) 981-987
25. Ganschow R., Schulz T., Meyer T., Broering D.C., and Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr 38 (2004) 198-203
26. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 5 (2005) 566-572
27. Juvonen E., Aalto S.M., Tarkkanen J., et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 32 (2003) 97-102
28. Seidel M.G., Fritsch G., Matthes-Martin S., et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 27 (2005) 532-536
29. Ault B.H., Honaker M.R., Osama Gaber A., et al. Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 17 (2002) 815-818
30. Newell K.A., Alonso E.M., Whitington P.F., et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 62 (1996) 370-375
31. Scheenstra R., Verschuuren E.A., de Haan A., et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transplant Infect Dis 6 (2004) 15-22
32. Benden C., Aurora P., Burch M., et al. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant 24 (2005) 2103-2108